Missing a key study means a strategic blind spot
Hundreds of medical publications monthly in your therapeutic area. Nobody has time to monitor them all, but missing a key competitor study means a strategic blind spot.
Why this happens
The evidence landscape moves faster than teams can track
In a competitive therapeutic area, new publications, congress abstracts, and regulatory updates appear weekly. A single missed competitor study can change the treatment paradigm.
Internal teams simply don’t have the bandwidth for systematic monitoring. Medical directors attend congresses and scan key journals, but coverage is incomplete. Important competitor data falls through the cracks.
The problem compounds over time. Without systematic tracking, competitive intelligence becomes reactive. By the time a team notices a competitor’s advantage, the strategic window has narrowed.
“We learned about a competitor’s pivotal Phase III result from a KOL — not from our own monitoring. That shouldn’t happen.”
— Head of Medical Affairs, MENA, Dermatology
Sound familiar?
Typical situations we hear
01
Too many publications, too little time
Your TA generates 200+ publications per month. The medical team scans 20. The other 180 may contain competitive signals.
02
Competitor data goes unnoticed
A competitor publishes RWE that undermines your positioning. Nobody noticed for 6 weeks.
03
No systematic monitoring process
Literature surveillance is ad hoc — dependent on individual effort and Google Scholar alerts. No structured process.
04
Guideline update missed
A treatment guideline in a key market was updated. The change affects your positioning. The team learns from a payer, not monitoring.
What breaks without intervention
The cost of doing nothing
Reactive strategy
Without proactive monitoring, your team is always responding rather than anticipating. Planning becomes firefighting.
KOL credibility risk
MSLs meet KOLs who are better informed about the latest publications. Field teams lose scientific credibility.
Missed strategic opportunities
A new publication supports your positioning — but nobody synthesizes it into usable materials. The advantage goes unexploited.
How MAG solves it
From ad hoc scanning to systematic intelligence
1
Monitoring scope definition
We define the search strategy — therapeutic area, key molecules, competitor brands, endpoints, and publication types to track.
2
AI-powered surveillance
Evidence Scanner™ runs continuous PubMed, congress, and guideline monitoring — flagging new publications within 24 hours.
3
Expert curation & analysis
Our medical experts review flagged publications, assess strategic importance, and produce structured intelligence briefs.
4
Regular reporting cadence
Weekly or monthly intelligence digests delivered to your team — with competitive alerts and strategic implications.
5
Strategic deep dives
For high-impact publications, we produce detailed evidence assessments with implications for positioning and payer strategy.
Services we use to solve this
What you get
Typical deliverables
Weekly literature digest
Competitive intelligence brief
Publication alert report
Guideline change assessment
Strategic evidence assessment
Competitor pipeline tracker
KOL publication tracking
Real work. Measurable outcomes.
Related case studies
EULAR 2024 rheumatology congress intelligence: 22 abstracts analyzed, 5 competitive signals identified
✓ Competitive intelligence report delivered to brand team within 48h
Read case study →
Rapid clinical summary for landmark CVOT: field-ready within 72 hours of publication
✓ MSL teams briefed within 72h, ahead of competitor response
Read case study →
Frequently asked
Common questions
What databases do you monitor?
We monitor PubMed, Embase, Cochrane Library, ClinicalTrials.gov, major congress databases, and HTA decision databases.
How is AI-powered monitoring different from Google Scholar alerts?
Evidence Scanner™ uses semantic search to identify relevant publications by meaning, not just keywords. It ranks by strategic importance.
Can you monitor specific competitor molecules?
Yes. We set up molecule-specific monitoring profiles tracking all publications, trial updates, and HTA decisions.
How often do you deliver reports?
Weekly, bi-weekly, or monthly cadences depending on your TA. Real-time alerts for high-priority publications are always included.
Do you provide analysis or just publication lists?
We provide curated intelligence briefs with strategic analysis — not raw lists. Each report includes competitive implications.
Still have questions about literature monitoring?
Book a 20-minute scoping call. We’ll review your situation and suggest the fastest path forward.
Book a scoping call →
Browse all services
Need systematic
competitive intelligence?
competitive intelligence?
Share your TA and key competitors — we’ll set up monitoring and deliver the first report within two weeks.
AI infrastructure
AI-powered.
Expert-validated.
We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.
Research
Structured PubMed queries with narrative or table outputs
Monitoring
Weekly literature digests by drug, target, or topic
AI-Enhanced EDC
Advisory board transcription + structured AI summary
Fact-Checker
Claim verification against your source documents
AI accelerates. Our experts validate.
Every output goes through expert medical review before it reaches your team. AI handles structure and speed — we handle scientific judgement and MLR readiness.
// Query: JAK inhibitor safety signal atopic dermatitis 2024
search("JAK inhibitor atopic dermatitis safety", {
years: [2024, 2025],
output: "structured_table"
})
// 1,890 records → 42 relevant
Processing 1,890 records...
Competitive Intelligence
New signal: JADE EXTEND 4-year data (JAAD 2024) — abrocitinib long-term safety stable, no new VTE/MACE events. Competitor advantage: longest follow-up in class...